Compare Biogen Inc (BIIB) vs Five9 Inc (FIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Five9 Inc — how do they compare? Biogen Inc trades at $210 (market cap $30.86B), while Five9 Inc trades at $33.69 (market cap $2.33B). The key difference: Biogen Inc is far larger — about 13.2× Five9 Inc's market cap. Which is the better fit depends on your goals.
| BIIB | FIVN | |
|---|---|---|
Market Cap | $30.86B | $2.33B |
Sector | Health | Technology |
52-Week High | $216.63 | $34.48 |
52-Week Low | $132.22 | $13.61 |
Enterprise Value | $37.93B | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $210.65, up 3.32% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 37.1 and net income margin of 8.32%, supported by positive cash flow trends. Recent news highlights the acquisition of RayThera Inc. and raised 2026 guidance, reflecting strategic growth initiatives.
Outlook is positive with analyst consensus price target of $234.47, though risks include competitive pressures and earnings volatility. Investment opportunity lies in pipeline expansion and Alzheimer's drug traction, balanced by margin compression concerns from legacy MS portfolio declines.
FIVN trades at $33.80, up 3.59% today, near its 52-week high of $34.58. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Revenue growth is accelerating, with 2025 revenue reaching $1.15 billion and net income turning positive at $39.42 million, marking a significant improvement from prior losses. Recent management appointments and AI-driven subscription growth are positive catalysts.
The outlook is positive given earnings momentum and analyst support, but risks include high valuation multiples, ongoing legal scrutiny, and dependence on competitive AI adoption. With 61% of analysts rating it a Buy and a consensus target of $32.67, near-term upside appears limited, but execution on guidance could drive further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Five9 Inc
Five9 provides cloud-native contact center software that enables digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement capabilities, and various software modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's artificial intelligence and automation portfolio supplements and enhances the firm's core CCaaS offerings, including solutions for digital self-service, agent assist technology, and workflow automation. Five9 also offers workforce optimization products that optimize call center efficiency through workforce management solutions, manage interaction quality, and track agent performance.
Read more on FIVN →
